Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neutropenic Complications|Breast Neoplasms|Chemotherapy-induced Neutropenia|Chemotherapeutic Toxicity
Interventions: DRUG: LA-EP2006|DRUG: Neulasta®
Sponsor: Sandoz
Collaborators: Sandoz GmbH